Cybin Inc. (NASDAQ:HELP - Get Free Report) has earned an average rating of "Buy" from the six ratings firms that are presently covering the firm, MarketBeat reports. Six analysts have rated the stock with a buy rating. The average 1-year target price among brokers that have issued a report on the stock in the last year is $47.33.
A number of research analysts have commented on HELP shares. Wells Fargo & Company raised their price target on shares of Cybin from $16.00 to $22.00 and gave the stock an "overweight" rating in a research note on Thursday, October 22nd. Wall Street Zen raised Cybin from a "strong sell" rating to a "sell" rating in a report on Sunday, October 25th. Barclays began coverage on Cybin in a research report on Friday, September 18th. They set an "overweight" rating and a $35.00 target price for the company. Finally, TD Cowen boosted their price target on Cybin from $8.00 to $62.00 and gave the company a "buy" rating in a research note on Thursday, August 20th.
Read Our Latest Analysis on Cybin
Cybin Stock Performance
NASDAQ HELP opened at $9.03 on Wednesday. The firm has a 50-day simple moving average of $11.81 and a 200 day simple moving average of $7.76. Cybin has a twelve month low of $3.76 and a twelve month high of $15.15. The stock has a market cap of $720.68 million, a PE ratio of -2.99 and a beta of 0.64.
Cybin (NASDAQ:HELP - Get Free Report) last announced its quarterly earnings data on Friday, August 14th. The company reported ($0.91) EPS for the quarter, missing analysts' consensus estimates of ($0.80) by ($0.11). Research analysts forecast that Cybin will post -2.95 earnings per share for the current fiscal year.
Insider Buying and Selling
In other news, CEO Michael Halstead bought 100,000 shares of the company's stock in a transaction that occurred on Monday, September 21st. The stock was acquired at an average price of $13.47 per share, for a total transaction of $1,347,000.00. Following the transaction, the chief executive officer directly owned 168,568 shares of the company's stock, valued at $2,270,610.96. This trade represents a 145.84% increase in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, insider Paul Glavine purchased 100,000 shares of the business's stock in a transaction that occurred on Tuesday, September 8th. The shares were purchased at an average cost of $12.47 per share, with a total value of $1,247,000.00. Following the completion of the acquisition, the insider directly owned 4,271,252 shares in the company, valued at $53,262,512.44. The trade was a 2.40% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Insiders purchased a total of 688,000 shares of company stock valued at $8,422,830 in the last ninety days. Insiders own 15.00% of the company's stock.
Institutional Inflows and Outflows
A number of institutional investors have recently modified their holdings of the company. AXQ Capital LP acquired a new position in shares of Cybin in the 2nd quarter worth approximately $75,000. Farther Finance Advisors LLC increased its holdings in Cybin by 927.4% during the 3rd quarter. Farther Finance Advisors LLC now owns 22,818 shares of the company's stock valued at $280,000 after purchasing an additional 20,597 shares in the last quarter. Pale Fire Capital SE bought a new position in Cybin in the 2nd quarter valued at $1,015,000. Finally, WealthPlan Investment Management LLC bought a new position in Cybin in the 3rd quarter valued at $1,272,000. Institutional investors own 17.94% of the company's stock.
About Cybin
(
Get Free Report)
Cybin Inc is a clinical-stage biopharmaceutical company focused on developing psychedelic-based therapeutics for mental health conditions. The company's research programs are designed to address disorders such as major depressive disorder and other conditions where existing treatments may not provide adequate relief.
Cybin's development platform has included investigational compounds such as CYB003, a deuterated psilocybin analog being studied for depression, and CYB004, an investigational N,N-dimethyltryptamine (DMT) formulation being evaluated for potential use in mental health treatment.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Cybin, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cybin wasn't on the list.
While Cybin currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.
